학술논문
891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S956-S956
Subject
Language
ISSN
0923-7534